Compare CCJ & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCJ | ALNY |
|---|---|---|
| Founded | 1987 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4B | 52.9B |
| IPO Year | N/A | 2004 |
| Metric | CCJ | ALNY |
|---|---|---|
| Price | $119.39 | $323.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 27 |
| Target Price | $114.38 | ★ $474.42 |
| AVG Volume (30 Days) | ★ 5.1M | 1.7M |
| Earning Date | 02-13-2026 | 02-12-2026 |
| Dividend Yield | ★ 0.15% | N/A |
| EPS Growth | ★ 364.36 | N/A |
| EPS | ★ 0.87 | 0.33 |
| Revenue | $2,487,042,049.00 | ★ $3,210,070,000.00 |
| Revenue This Year | $10.50 | $70.40 |
| Revenue Next Year | $8.14 | $44.32 |
| P/E Ratio | ★ $130.99 | $994.86 |
| Revenue Growth | 23.88 | ★ 53.24 |
| 52 Week Low | $35.00 | $205.87 |
| 52 Week High | $135.24 | $495.55 |
| Indicator | CCJ | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 27.93 |
| Support Level | $109.00 | $333.00 |
| Resistance Level | $128.15 | $355.49 |
| Average True Range (ATR) | 6.88 | 11.90 |
| MACD | -2.00 | -1.11 |
| Stochastic Oscillator | 37.93 | 2.46 |
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.